Toxivenol Tablets

Toxivenol (Tablets)
(Troxerutin / Carbazochrome)


CONTENT:
Tablets. Tablet contains troxerutin 300 mg, carbazochrome 3.0 mg.
 

PHARMACOTHERAPEUTIC GROUP:
Angioprotector. Agents, decreasing capillary permeability. Hemostatic agent.
 
PHARMACOLOGICAL PROPERTIES:
Optimal combination of components troxerutin and carbazochrome causes high pharmacological efficacy of drug product, that enables to treat vascular diseases and hemorrhage syndromes at capillary weakness. Troxerutin, known also as vitamin P4, is a bioflavonoid, which increases vascular resistance (vascular protecting action) and decreases permeability, preventing from excessive penetration of blood liquids into tissues (antiedema and impermeability action). Pharmacological effect causes increase of vitamin C activity, which protects from permeability of membranes and augments hyaluronic acid production; it is a mucopolysaccharide, responsible for density of vascular walls. Besides, reduction in release of histamine, which is potent vasodilator and pro-edematous agent, is observed.
Carbazochrome is an orthoquinone, adrenalin oxidation product without sympathomimetic activity resulted from absence of secondary amine group and o-diphenol group. Vasoconstrictive local influence on small vessels of bleeding zone results in decrease of bleeding duration. This phenomenon occurs without arterial pressure increase and changes of cardiac function. It was found, that carbazochrome evidently influences capillary permeability and strength, tone and contraction strength of vessels.
Solution for injection is used in urgent treatment and in case of necessity of rapid therapeutic effect.
 
THERAPEUTIC INDICATIONS:
- chronic venous insufficiency, varix dilatation, surface trombophlebitis, periphlebitis, posttraumatic edema, haematoma, trophic disturbances during chronic venous insufficiency (dermatitis, trophic ulcer);
- hemorrhoidal bolus;
- diabetic angiopathy;
- retinopathy.
 
CONTRAINDICATIONS:
- Hypersensitivity to drug components.
 
SIDE EFFECTS:
It has good tolerability without any adverse effects.
 
DOSAGE AND ADMINISTRATION:
Dosage regimen and course of treatment are individual: 3-9 ml per day intramuscularly, 2-4 tablets per day.
 
OVERDOSE:
There are no reported cases of accidental and deliberate drug overdose.
 
INTERACTION WITH DRUGS:
Increases ascorbic acid influence on structure and permeability of vascular wall. The ampoule contents cannot be mixed with the solutions, containing ascorbic acid.
 
APPLICATION AT PREGNANCY AND LACTATION:
Drug product is not recommended at pregnancy and lactation.
 
INFLUENCE ON ABILITY TO DRIVE AND OPERATE OTHER MECHANISMS:
The product does not influence the rate of psychophysical reactions during treatment.
 
PACKAGING:
10 tablets in blister.
3 blisters with leaflet in carton box.
Solution for injections in glass ampoules, 3 ml volume.
10 ampoules in strip cellular pack with leaflet, in carton box.